Davunetide (NAPVSIPQ; NAP) is an eight amino acid peptide identified as the active component of activity-dependent neuroprotective protein (ADNP). It has been found to be neuro-protective at femtomolar concentrations in vitro against the neural toxicity of a wide range of compounds. Davunetide has been investigated for Parkinson′s disease and schizophrenia and in clinical trials for Alzheimner′s Disease, targeting microtubule-tau Interaction.